血管内皮生长因子对青光眼的视神经保护机制的研究进展

doi:10.16150/j.1671-2870.2021.03.011

摘要/Abstract

关键词: 青光眼, 血管内皮生长因子, 视神经保护, 视网膜神经节细胞

中图分类号:

R775

孙俊, 余欢, 黄守约. 血管内皮生长因子对青光眼的视神经保护机制的研究进展[J]. 诊断学理论与实践, 2021, 20(03): 290-293.

参考文献 38

[1]	Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development[J]. Cell, 2019, 176(6):1248-1264. doi: 10.1016/j.cell.2019.01.021 URL
[2]	Song P, Wang J, Bucan K, et al. National and subnatio-nal prevalence and burden of glaucoma in China: a systematic analysis[J]. J Glob Health, 2017, 7(2):020705. doi: 10.7189/jogh.07.020705 URL
[3]	Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review[J]. JAMA, 2014, 311(18):1901-1911. doi: 10.1001/jama.2014.3192 pmid: 24825645
[4]	Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy[J]. Nat Rev Drug Discov, 2016, 15(6):385-403.
[5]	Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis[J]. Rom J Morphol Embryol, 2018, 59(2):455-467.
[6]	Alkharsah KR. VEGF upregulation in viral infections and its possible therapeutic implications[J]. Int J Mol Sci, 2018, 19(6):1642. doi: 10.3390/ijms19061642 URL
[7]	Chen R, Lee C, Lin X, et al. Novel function of VEGF-B as an antioxidant and therapeutic implications[J]. Pharmacol Res, 2019, 143:33-39. doi: 10.1016/j.phrs.2019.03.002 URL
[8]	van Bergen T, Etienne I, Cunningham F, et al. The role of placental growth factor(PlGF) and its receptor system in retinal vascular diseases[J]. Prog Retin Eye Res, 2019, 69:116-136. doi: S1350-9462(18)30060-0 pmid: 30385175
[9]	Wang J, Huang Y, Zhang J, et al. Pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis[J]. Clin Chim Acta, 2016, 461:165-171. doi: 10.1016/j.cca.2016.08.008 URL
[10]	Tian YI, Zhang X, Torrejon K, et al. A bioengineering approach to Schlemm′s canal-like stem cell differentiation for in vitro glaucoma drug screening[J]. Acta Biomater, 2020, 105:203-213. doi: 10.1016/j.actbio.2020.01.033 URL
[11]	Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review[J]. JAMA, 2021, 325(2):164-174. doi: 10.1001/jama.2020.21899 URL
[12]	汤加, 陈有信. 血管内皮生长因子的神经保护作用[J]. 中华实验眼科杂志, 2020, 38(1): 64-67.
[13]	Lange C, Storkebaum E, de Almodóvar CR, et al. Vascular endothelial growth factor: a neurovascular target in neurological diseases[J]. Nat Rev Neurol, 2016, 12(8):439-454.
[14]	Cattin AL, Burden JJ, Van Emmenis L, et al. Macrophage-induced blood vessels guide schwann cell-mediated regeneration of peripheral nerves[J]. Cell, 2015, 162(5):1127-1139. doi: 10.1016/j.cell.2015.07.021 URL
[15]	Po$\grave{\text z}$arowska D, Po$\grave{\text z}$arowski P, The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy[J]. Cent Eur J Immunol, 2016, 41(3):311-316.
[16]	Sun C, Zhang H, Jiang J, et al. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy[J]. Int Ophthalmol, 2020, 40(2):467-475. doi: 10.1007/s10792-019-01207-4 URL
[17]	张水华, 曲毅. 血管内皮生长因子B对小鼠视神经保护作用的研究[J]. 中华眼科杂志, 2009, 45(1):38-42.
[18]	Shen J, Xiao R, Bair J, et al. Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study[J]. Cell Death Dis, 2018, 9(10):1018. doi: 10.1038/s41419-018-1049-0 URL
[19]	Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury[J]. Am J Pathol, 2007, 171(1):53-67. pmid: 17591953
[20]	Fahy ET, Chrysostomou V, Crowston JG. Mini-review: impaired axonal transport and glaucoma[J]. Curr Eye Res, 2016, 41(3):273-283.
[21]	朱轶冰, 陆佩华, 盛祖杭. AD发病机制的新探索:轴浆运输障碍假说[J]. 生理科学进展, 2008, 39(1):5-9.
[22]	党鸿辛, 辛晓蓉. 青光眼视神经损伤机制的研究进展[J]. 眼科新进展, 2016, 36(7):680-683.
[23]	Foxton R, Osborne A, Martin KR, et al. Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism[J]. Cell Death Dis, 2016, 7(5):e2212. doi: 10.1038/cddis.2016.110 URL
[24]	Yang P, Sun X, Kou ZW, et al. VEGF axonal transport dependent on kinesin-1B and microtubules dynamics[J]. Front Mol Neurosci, 2017, 10:424. doi: 10.3389/fnmol.2017.00424 URL
[25]	Dapper JD, Crish SD, Pang IH, et al. Proximal inhibition of p38 MAPK stress signaling prevents distal axonopathy[J]. Neurobiol Dis, 2013, 59:26-37. doi: 10.1016/j.nbd.2013.07.001 pmid: 23859799
[26]	Tsai T, Grotegut P, Reinehr S, et al. Role of heat shock proteins in glaucoma[J]. Int J Mol Sci, 2019, 20(20):5160. doi: 10.3390/ijms20205160 URL
[27]	Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling[J]. Nat Rev Mol Cell Biol, 2016, 17(10):611-625.
[28]	Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma[J]. Am J Pathol, 2013, 182(4):1379-1390. doi: 10.1016/j.ajpath.2012.12.032 URL
[29]	Almasieh M, Wilson AM, Morquette B, et al. The mole-cular basis of retinal ganglion cell death in glaucoma[J]. Prog Retin Eye Res, 2012, 31(2):152-181. doi: 10.1016/j.preteyeres.2011.11.002 URL
[30]	Lawler T, Liu Y, Christensen K, et al. Dietary antioxidants, macular pigment, and glaucomatous neurodegene-ration: a review of the evidence[J]. Nutrients, 2019, 1(5):1002.
[31]	Li Y, Zhang F, Nagai N, et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats[J]. J Clin Invest, 2008, 118(3):913-923.
[32]	Shukla S, Saxena S, Singh BK, et al. BH3-only protein BIM: an emerging target in chemotherapy[J]. Eur J Cell Biol, 2017, 96(8):728-738. doi: 10.1016/j.ejcb.2017.09.002 URL
[33]	Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases[J]. Prog Retin Eye Res, 2015, 49:67-81. doi: 10.1016/j.preteyeres.2015.06.002 pmid: 26113211
[34]	Silverman SM, Wong WT. Microglia in the retina: roles in development, maturity, and disease[J]. Annu Rev Vis Sci, 2018, 4:45-77. doi: 10.1146/annurev-vision-091517-034425 pmid: 29852094
[35]	Galán-Ganga M, García-YagüeáJ, Lastres-Becker I. Role of MSK1 in the induction of NF-κB by the chemokine CX3CL1 in microglial cells[J]. Cell Mol Neurobiol, 2019, 39(3):331-340. doi: 10.1007/s10571-019-00664-w pmid: 30830503
[36]	Perbal A. 8th international workshop on the CCN family of genes-Nice November 3-8, 2015[J]. J Cell Commun Signal, 2016, 10(1):87-101. doi: 10.1007/s12079-016-0319-9 pmid: 27074941
[37]	Rothhammer V, Borucki DM, Tjon EC, et al. Microglial control of astrocytes in response to microbial metabolites[J]. Nature, 2018, 557(7707):724-728. doi: 10.1038/s41586-018-0119-x URL
[38]	Hoguet A, Chen PP, Junk AK, et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2019, 126(4):611-622. doi: 10.1016/j.ophtha.2018.11.019 URL

血管内皮生长因子对青光眼的视神经保护机制的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 10

编辑推荐

Metrics

本文评价

[1]	王利华, 张淼, 石朔, 郭睿, 李彪,. 治疗基因VEGF_(165)和报告基因NIS共表达载体的构建和鉴定[J]. 诊断学理论与实践, 2011, 10(05): 423-427.
[2]	倪培华, 傅毅, 陈宁, 应雅韵,. 血管内皮生长因子基因多态性与脑梗死的关系[J]. 诊断学理论与实践, 2010, 9(06): 560-565.
[3]	陆晨鸣, 祝肇荣,. 倍频视野计与Octopus101视野计在青光眼患者中的应用[J]. 诊断学理论与实践, 2010, 9(05): 514-517.
[4]	倪效, 燕敏, 严超, 刘炳亚, 陈雪华, 瞿颖, 计俊, 俞焙秦, 朱正纲,. 血管内皮生长因子C与胃癌淋巴管生长关系的研究[J]. 诊断学理论与实践, 2008, 7(02): 198-201.
[5]	胡伟国, 郑民华,. 血管内皮生长因子C、D与肿瘤淋巴血管转移[J]. 诊断学理论与实践, 2006, 5(01): 75-77.
[6]	吴瑾, 薛建, 徐筱春, 莫剑忠,. 胃癌和癌前病变患者血清中血管内皮生长因子含量与临床病理特征关系[J]. 诊断学理论与实践, 2005, 4(06): 497-498.
[7]	陈锦先,王争,王平治. 血管内皮生长因子基因表达与Dukes A和B期大肠癌预后关系的研究[J]. 诊断学理论与实践, 2005, 4(02): 137-139.
[8]	侯振江,张宗英. 血管内皮生长因子及其受体检测在恶性肿瘤诊疗中的应用[J]. 诊断学理论与实践, 2005, 4(01): 92-94.
[9]	钟璐,陈芳源,王海荣,滕晔,王晨,欧阳仁荣. 槲皮素对HL鄄60细胞形态及血管内皮生长因子表达的影响[J]. 诊断学理论与实践, 2004, 3(06): 36-38.
[10]	刘斌,郑佐娅,陈燕,曹玲仙,秦慧,赵旭霁,陆丽华. 非小细胞肺癌患者血清血管内皮生长因子测定的临床意义[J]. 诊断学理论与实践, 2003, 2(03): 34-36.